SCHEMBL6481165

SCHEMBL6481165

Cn1cc(C(=O)NCc2ccc(Cl)cc2)c(=O)c2sc(I)cc21

nearest known ligand 0.58

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.53
KCNH2 Q12809 2/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6479266 0.86 KCNH2 (0.53) MAPTKCNH2MEN1KMT2A
SCHEMBL6481474 0.86 KCNH2 (0.53) MAPTKCNH2MEN1KMT2A
SCHEMBL6669967 0.83 KCNH2 (0.66) KCNH2
SCHEMBL6481383 0.82 MAPT (0.49) MAPTKCNH2MEN1KMT2A
SCHEMBL6478861 0.80 KCNH2 (0.75) KCNH2MEN1KMT2A
SCHEMBL7938457 0.80 MAPT (0.67) MAPTKCNH2MEN1KMT2A
SCHEMBL7842626 0.76 MAPT (0.68) MAPTKCNH2MEN1KMT2A
SCHEMBL6814897 0.76 MAPT (0.68) MAPTKCNH2MEN1KMT2A
SCHEMBL6634322 0.76 KCNH2 (0.53) KCNH2
SCHEMBL6325235 0.76 KCNH2 (0.65) MAPTKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861438-B2 Antiviral agents PFIZER (US) 2005-03-01 US disclosed
EP-1467999-A1 OXOTHIENO[3,2-B]PYRIDINECARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2004-10-20 EP disclosed
US-20040138449-A1 Antiviral agents PHARMACIA & UPJOHN COMPANY 2004-07-15 US disclosed
WO-2003059912-A1 OXOTHIENO (3, 2-B) PYRIDINECARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138449-A1 Antiviral agents IRF3, IFNAR1, EIF2AK2 MAPT 3921/4885KCNH2 766/4885MEN1 1116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.